OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC

Regulatory Filings • Jun 15, 2023

/*<![CDATA[*/ /**/ /**/ /**/ h1{margin-top:24.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;font-size:24.0pt;font-family:"Calibri","sans-serif";}h2{margin-top:18.0pt;margin-right:0cm;margin-bottom:4.0pt;margin-left:0cm;font-size:18.0pt;font-family:"Calibri","sans-serif";}h3{margin-top:14.0pt;margin-right:0cm;margin-bottom:4.0pt;margin-left:0cm;font-size:14.0pt;font-family:"Calibri","sans-serif";}h4{margin-top:12.0pt;margin-right:0cm;margin-bottom:2.0pt;margin-left:0cm;font-size:12.0pt;font-family:"Calibri","sans-serif";}h5{margin-top:11.0pt;margin-right:0cm;margin-bottom:2.0pt;margin-left:0cm;font-size:11.0pt;font-family:"Calibri","sans-serif";}h6{margin-top:10.0pt;margin-right:0cm;margin-bottom:2.0pt;margin-left:0cm;font-size:10.0pt;font-family:"Calibri","sans-serif";}link{ color: blue }visited{ color: #954F72 } .t{size:595.0pt 842.0pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.t{}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";}span.ab{z-index:251657728; width:224px;height:116px}p.ad{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Calibri","sans-serif";border:none}span.z{font-family: "Times New Roman","serif"}span.aa{color:black}span.x{font-family: "Times New Roman","serif";color:black}span.w{font-family:"Times New Roman","serif";color:#1155CC}span.v{font-family:"Times New Roman","serif"} span.u{font-family:"Times New Roman","serif";color:black} .fr-view-element{font-family: sans-serif;font-size: 12pt;line-height: 140%;padding: 20px;box-sizing: border-box;overflow-x: auto;min-height: 60px;text-align: left;margin-bottom: 10px;width: 837px;} .fr-view-element img{padding: 0 1px;} .fr-view-element .t{margin: 63.8pt 1.6cm 62.35pt 1.6cm;} .fr-view-element p{font-size: 10pt;} /**/ /**/ /**/ /*]]>*/ National Storage Mechanism | Additional information

RNS Number : 8487C

Oxford Cannabinoid Tech.Holdings

15 June 2023

 

Oxford Cannabinoid Technologies Holdings plc (OCT) have launched new video content with Doceo.

Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines for approval by global regulatory agencies and targeting the US$ multi-billion pain market, is pleased to announce a new video on Doceo.

OCT is a dynamic biotechnology company aiming to revolutionise drug development by utilising a diverse range of compounds, including proprietary cannabinoid derivatives, natural phytocannabinoids, and innovative new chemical entities (NCEs) that target the endocannabinoid system. Their strategic approach ensures the creation of a drug development portfolio that maximises the therapeutic potential of cannabinoids, while also driving long-term market value and market exclusivity in all activities.

[Video content removed for conversion]

For an update on OCT, visit: https://doceo.tv/funds/oxford-cannabinoid-technologies/. For further information on Doceo please visit www.doceo.tv or contact the team on info@doceo.tv

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFAMPTMTIBMFJ